The FDA approved X4 Pharmaceuticals drug Xolremdi for treating WHIM syndrome. The molecule, which addresses the underlying cause of this rare immunodeficiency, was licensed from Sanofi’s Genzyme subsidiary.
Voyager will gain worldwide rights to its Huntington's disease therapy candidate, transfer rights to another product candidate to Neurocrine and pay Sanofi $20 million.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
A shining light for the biotechnology industry, for Kendall Square, and for patients with rare diseases has passed away. Henri Termeer founded and led Genzyme for close to 30 years, greatly influencing the rise of biotech and bringing a patient-centric approach to the business.
The company's CXCR4 inhibitors work to modulate the tumor microenvironment - improving the efficacy of the immune system in fighting cancer.
In the latest pharma-academia partnership, Genzyme and Cleveland Clinic researchers will align their efforts to better understand and treat multiple sclerosis. Their new research collaboration will span at least five years and will be led by a steering committee of researchers from both organizations, Genzyme said. Initially, their work will focus on better understanding the […]
A company formed to develop protein therapeutics to treat lysosomal storage diseases — rare genetic disorders that affect the metabolism of certain natural biological substances in cells — is raising $5 million in a series A financing round, according to a filing with the U.S. Securities and Exchange Commission With the investment, the company is […]
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Current medical news and unique business news for anyone who cares about healthcare. J&J company responds to FDA warning Johnson & Johnson’s (NYSE: JNJ) subsidiary DePuy Orthopaedics received a warning letter from U.S. regulators not to sell joint replacement products without proper approval. The Dec. 8 letter said a federal investigation at DePuy’s Warsaw, Indiana […]
French pharmaceutical company Sanofi (NYSE: SNY) said it will shut down its Bridgewater, New Jersey-based research and development facilities and consolidate them in its Boston hub. The company said it could not say how many jobs would be cut when its Bridgewater r&d facilities shut in the fourth quarter of 2012. It will set up […]
Among today’s current medical news: The Genzyme-Sanofi effect, seeking clarity from Judge Vinson, pharma's friendly nurses, doctor tweets and healthcare social media, and a Medicare fraud sweep that won't make a dent.
Genzyme Corp. sells off its diagnostics business to Sekisui Chemical Co. Ltd. for $265 million in cash. Genzyme Corp. (NSDQ:GENZ) is planning to sell off its diagnostics business to Tokyo-based Sekisui Chemical Co. Ltd. (TYO:4204) for $265 million in cash. The Cambridge, Mass.-based biotech giant said Sekisui will buy “substantially all of the assets” of […]
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
Genzyme Corp. (NASDAQ:GENZ) CEO Henri Termeer has cut his stake in Danvers, Massachusetts-based Abiomed Inc. (NASDAQ:ABMD) by about 5.4 percent over the past year.
Robert Edwards of Britain, an 85-year-old professor emeritus at the University of Cambridge who started working on in-vitro fertilization as early as the 1950s, won the 2010 Nobel Prize in medicine on Monday for developing the breakthrough that has helped millions of infertile couples worldwide have children, according to the Associated Press in the Washington Post.
ambridge, Mass., biotech firm Genzyme Corp. is selling its genetic testing business to Laboratory Corp. of America Holdings for $925 million so it can focus on its core growth areas.
Stephen Hemsley, CEO of UnitedHealth Group, topped Modern Healthcare's list of highest-paid executives at $106 million -- $7.5 million in salary and benefits and $98.5 million in stock options in 2009. Hemsley is not alone, says an editorial in St. Louis Today. The CEOs at insurance giants Cigna, Humana, Aetna, Coventry Health Systems and WellPoint all took home between $10 million and about $18 million.
That'd be medical resident, according to the Christian Science Monitor, which includes the job at No. 5 on its list of the most stressful.